# Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

> **NCT05564416** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Bladder Carcinoma
- Bladder Urothelial Carcinoma
- Muscle Invasive Bladder Carcinoma
- Renal Pelvis and Ureter Urothelial Carcinoma
- Stage II Bladder Cancer AJCC v8
- Stage III Bladder Cancer AJCC v8
- Stage IVA Bladder Cancer AJCC v8
- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Cystoscopy
- **DRUG:** Erdafitinib
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT05564416
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-12
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Feasibility issues
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564416, "Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05564416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*